Combined with our previous study on lipid profiles (37) and another lipid metabolism enzyme, LPEAT (37), in patients with SCAP, we speculated that the elevation of LPCAT may be related to lung tissue destruction in SCAP because LPCAT is abundantly expressed in type II alveolar epithelial cells (8). Here, MBOAT2 is linked to syringocystadenoma papilliferum.